The story has been updated to provide additional details and comments from Adaptive Biotechnologies' CEO, Chad Robins.

NEW YORK (GenomeWeb News) – Immune sequencing services company Adaptive Biotechnologies has raised $5 million toward a targeted $20 million financing round.

In a Form D filed with the US Securities and Exchange Commission recently, it said that the securities offered were in the form of equity. Adaptive Bio's CEO Chad Robins told GenomeWeb Daily News that that the $5 million was the first tranche of a Series C round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.